a Phase I/IIa, Open Label, Uncontrolled Study to Evaluate the Safety and Efficacy of Astarabine (BST-236) as Single Agent in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Disease

Trial Profile

a Phase I/IIa, Open Label, Uncontrolled Study to Evaluate the Safety and Efficacy of Astarabine (BST-236) as Single Agent in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Astarabine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms BSTPHASE1-01
  • Sponsors BioSight
  • Most Recent Events

    • 09 Aug 2017 According to a BioSight media release, treatment of last patient has been completed and top-line results from this study is expected in the coming months.
    • 08 Aug 2017 According to a BioSight media release, this study was extended by additional dose-escalating cohorts, either relapsed/refractory or older newly-diagnosed unfit for standard therapy.
    • 11 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top